Embecta (NASDAQ:EMBC – Get Rating) is one of 220 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Embecta to related companies based on the strength of its dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.
Profitability
This table compares Embecta and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Embecta | 8.44% | -23.46% | 17.55% |
| Embecta Competitors | -514.02% | -123.72% | -26.52% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Embecta and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Embecta | 2 | 1 | 0 | 0 | 1.33 |
| Embecta Competitors | 1120 | 3729 | 7865 | 172 | 2.55 |
Valuation and Earnings
This table compares Embecta and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Embecta | $1.13 billion | $223.60 million | 17.41 |
| Embecta Competitors | $1.19 billion | $60.41 million | -1.09 |
Embecta’s rivals have higher revenue, but lower earnings than Embecta. Embecta is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
93.5% of Embecta shares are held by institutional investors. Comparatively, 46.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 0.2% of Embecta shares are held by company insiders. Comparatively, 14.0% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Embecta has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Embecta’s rivals have a beta of 1.36, suggesting that their average share price is 36% more volatile than the S&P 500.
Dividends
Embecta pays an annual dividend of $0.60 per share and has a dividend yield of 2.1%. Embecta pays out 37.0% of its earnings in the form of a dividend. As a group, “Surgical & medical instruments” companies pay a dividend yield of 1.2% and pay out 45.3% of their earnings in the form of a dividend. Embecta is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
Summary
Embecta beats its rivals on 8 of the 15 factors compared.
Embecta Company Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
